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Abstract: 5-methyl cytosine (5mC) is a key epigenetic mark entwined with gene expression and
the specification of cellular phenotypes. Its distribution around gene promoters sets a barrier
for transcriptional enhancers or inhibitor proteins binding to their target sequences. As a result,
an additional level of regulation is added to the signals that organize the access to the chromatin and
its structural components. The tumor suppressor gene RASSF1A is a microtubule-associated and
multitasking scaffold protein communicating with the RAS pathway, estrogen receptor signaling,
and Hippo pathway. RASSF1A action stimulates mitotic arrest, DNA repair and apoptosis, and controls
the cell cycle and cell migration. De novo methylation of the RASSF1A promoter has received much
attention due to its increased frequency in most cancer types. RASSF1A methylation is preceded
by histones modifications and could represent an early molecular event in cell transformation.
Accordingly, RASSF1A methylation is proposed as an epigenetic candidate marker in many cancer
types, even though an inverse correlation of methylation and expression remains to be fully ascertained.
Some findings indicate that the epigenetic abrogation of RASSF1A can promote the alternative
expression of the putative oncogenic isoformRASSF1C. Understanding the complexity and significance
of RASSF1A methylation is instrumental for a more accurate determination of its biological and
clinical role. The review covers the molecular events implicated in RASSF1A methylation and gene
silencing and provides a deeper view into the significance of the RASSF1A methylation patterns in
a number of gastrointestinal cancer types.
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1. The Tumor Suppressor RASSF1A
The RASSF1 locus, in the cytogenetic band chr3:p21.31, expresses eight main transcript variants
under the control of two promoters overlapped to the CpG islands A and C [1]. The major,
ubiquitous transcripts expressed by the RASSF1 locus are RASSF1A and RASSF1C [1,2]. RASSF1B and
RASSF1C differ in the first exon. Additional RASSF1 isoforms, RASSF1D, RASSF1E, RASSF1F,
RASSF1G, and RASSF1H derive from alternative splicing of RASSF1A. A schematic representation of
the RASSF1 locus is reported in Figure 1.
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Figure 1. Schematic representation of the RASSF1 locus and its transcription map. White boxes 
represent the exons and the bold line represents the introns. RASSF1A (red), RASSF1B (blue), and 
RASSF1C (green) variants are generated by differential promoter and first exon usage (arrows). 
RASSF1D, RASSF1E, RASSF1F, RASSF1G, and RASSF1H are variants derived from alternative 
splicing of RASSF1A. Two CpG islands (grey bands below exons 1 and 2) are associated to RASSF1 
promoter region: CpG island A (736 bp, 85 CpGs, chr3:50,340,373-50,341,109, GRCh38/hg38) 
extending in the promoter region of RASSF1A; CpG island C (1364 bp, 139 CpGs, chr3:50,336,834-
50,338,198, GRCh38/hg38) in the regulatory region of RASSF1B and RASSF1C. A CpG island is 
defined as a sequence with a length greater than 200 bp, a GC content greater than 50% and a ratio 
greater than 0.6 of the observed number of CG dinucleotides with respect to the expected number on 
the basis of the number of Gs and Cs nucleotides in the segment. 
The first exon of RASSF1A contains a cysteine-rich domain, reminiscent of the diacylglycerol-
binding–CRD domain [1]. This domain is lacking in RASSF1B and RASSF1C. Most studies published 
on RASSF1 concern RASSF1A and RASSF1C. The function of RASSF1B, RASSF1D, RASSF1E, 
RASSF1F, RASSF1G, and RASSF1H has received little research attention. 
The RASSF1A isoform is transcribed in the RASSF1 locus about 180 base pairs aside to the gene 
ZMYND10 (protein name BLU). Three binding sites for the insulator CCCTC-binding factor (CTCF) 
are overlapped to the 3′ end of ZMYND10, in a region between −453 and −2050 bp from the RASSF1A 
transcription start site. The insulator CTCF binds insulator sequences that separate functionally the 
transcription start sites of the two close genes forming two distinct epigenetic domains [3]. For this 
reason, despite their proximity, RASSF1A has often been found down-regulated in cancer as opposed 
to ZMYND10 [4]. 
The 3p.21.31 region may harbor candidate tumor suppressor genes due to the frequent copy 
number loss in various cancer types [5–7], including HYAL2, TUSC2, RASSF1, ZMYND10, NPRL2, 
CYB561D2, TMEM115. and CACNA2D2 [8]. The gene RASSF1A (RASSF1-association domain family 
1, isoform A) was initially identified as a potential RAS binding molecule due to the presence of a 
RAS-association domain in its primary sequence. RASSF1A binds RAS in the GTP-bound form to 
promote apoptosis [9]. RASSF1A has been proposed to act as a tumor suppressor, since the loss of its 
function induces cell proliferation and tumorigenesis [10], and may be implicated in microtubule 
Figure 1. Schematic representation of theRASSF1 locus and its transcription map. White boxes represent
the exons and the bold line represents the introns. RASSF1A (red),RASSF1B (blue), andRASSF1C (green)
variants are generated by differential promoter and first exon usage (arrows). RASSF1D, RASSF1E,
RASSF1F,RASSF1G, andRASSF1H are variants derived from alternative splicing ofRASSF1A. Two CpG
islands (grey bands below exons 1 and 2) are associated to RASSF1 promoter region: CpG island
A (736 bp, 85 CpGs, chr3:50,340,373-50,341,109, GRCh38/hg38) extending in the promoter region of
RASSF1A; CpG island C (1364 bp, 139 CpGs, chr3:50,336,834-50,338,198, GRCh38/hg38) in the regulatory
region of RASSF1B and RASSF1C. A CpG island is defined as a sequence with a length greater than
200 bp, a GC content greater than 50% and a ratio greater than 0.6 of the observed number of CG
dinucleotides with respect to the expected number on the basis of the number of Gs and Cs nucleotides
in the segment.
The first exon of RASSF1A contains a cysteine-rich domain, reminiscent of the
diacylglycerol-binding–CRD domain [1]. This domain is lacking in RASSF1B and RASSF1C.
Most studies published on RASSF1 concern RASSF1A and RASSF1C. The function of RASSF1B,
RASSF1D, RASSF1E, RASSF1F, RASSF1G, and RASSF1H has received little research attention.
The RASSF1A isoform is transcribed in the RASSF1 locus about 180 base pairs aside to the gene
ZMYND10 (protein name BLU). Three binding sites for the insulator CCCTC-binding factor (CTCF)
are overlapped to the 3′ end of ZMYND10, in a region between −453 and −2050 bp from the RASSF1A
transcription start site. The insulator CTCF binds insulator sequences that separate functionally the
transcription start sites of the two close genes forming two distinct epigenetic domains [3]. For this
reason, despite their proximity, RASSF1A has often been found down-regulated in cancer as opposed
to ZMYND10 [4].
The 3p.21.31 region may harbor candidate tumor suppressor genes due to the frequent copy
number loss in various cancer types [5–7], including HYAL2, TUSC2, RASSF1, ZMYND10, NPRL2,
CYB561D2, TMEM115. and CACNA2D2 [8]. The gene RASSF1A (RASSF1-association domain family
1, isoform A) was initially identified as a potential RAS binding molecule due to the presence of
a RAS-association domain in its primary sequence. RASSF1A binds RAS in the GTP-bound form to
promote apoptosis [9]. RASSF1A has been proposed to act as a tumor suppressor, since the loss of
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its function induces cell proliferation and tumorigenesis [10], and may be implicated in microtubule
stabilization, apoptosis, cell cycle, and DNA repair [11–15]. The most relevant cell protection functions
operated by RASSF1A are mediated by the interaction with the Hippo and the Wnt pathways and
the modulator of apoptosis 1 (MOAP1) [16–21]. Aged RASSF1A(−/−) mice are prone to spontaneous
tumorigenesis [20], particularly in the liver [22], suggesting that RASSF1A function is essential for
a correct homeostasis and healthy state of cells. Moreover, DNA methylation and silencing of RASSF1A,
along with another tumor suppressor gene, HIC1, transforms mesenchymal stem cells into cancer stem
cells [23], implying that RASSF1A methylation (RASSF1Am) is part of a delicate hierarchical network
of oncogenic gene silencing patterns involved in neoplastic transformation. In accordance with the
above mentioned observations, RASSF1A is expressed in all normal tissues and at a lower level than
RASSF1C [24]. Reverting RASSF1A down-regulation in cancer cell lines restores controlled growth
and colony formation, as well as decreased cell migration and apoptosis [10,25–30].
2. Biological Role of RASSF1C
The function of the isoform RASSF1C is less well defined with respect to that of RASSF1A,
although various studies converge upon the idea that the molecule could promote cell survival and
proliferation, to thereby exert an opposite role to that attributed to RASSF1A. RASSF1C has been
demonstrated to be nuclear or perinuclear with translocation to the cytosol upon DNA damage [31],
or localized to microtubules similarly to RASSF1A [32,33]. The Daxx-RASSF1C complex has been
shown to be involved in the DNA damage response and the SAPK/JNK signaling pathway [34].
Initially, RASSF1C has been shown to induce cell cycle arrest in cancer cell lines suggesting that,
like RASSF1A, the RASSF1C gene could act as a tumor suppressor function [35]. Other findings support
a potential role of RASSF1C as oncogene, promoting beta-catenin (CTNNB1) accumulation in HeLa
cells [36] and proliferation of lung cancer cells [37], supporting cell migration and attenuated apoptosis
in breast cancer [38].
3. DNA Methylation Changes
Methylation of cytosine to 5-methylcytosine (5mC) is a central epigenetic modification that
feeds back on cellular processes including genome regulation, organism development and disease.
DNA methyltransferases DNMT1, DNMT3a, and DNMT3b establish specific 5mC patterns during
embryonic development and cell differentiation and maintain them over many cell division cycles in
adults [39]. DNMT1 is the enzyme responsible for the addition of methyl groups, immediately following
DNA replication, preferentially to hemimethylated DNA. DNMT1 is post-transcriptionally regulated
by a mutually exclusive Ser/Thr phosphorylation and Lys methylation under the control of
PI3K-AKT-mTOR pathway [40–42]. DNMT3a and DNMT3b are preferentially implicated in de
novo DNA methylation, that is the addition of one methyl group to cytosine in unmethylated
CpG dinucleotides after DNA duplication [43]. DNA methylation can be reversed by Ten-eleven
translocation (TET) enzymes (TET1, TET2, TET3), which are responsible for the fine-tuning methylation
of patterns [44]. TET enzymes oxidize the methyl group of 5mC to yield 5-hydroxymethylcytosine,
which facilitates both passive and active demethylation. The implications of methylation-demethylation
epigenetic disequilibrium and of TET enzymes in gastrointestinal cancers have been observed in various
studies [45–51]. Understanding DNA methylation-demethylation dynamics, and their epigenetic
interplays in modulating transcription will open new perspectives for research on cellular differentiation
and oncogenic transformation (see Ambrosi et al. [52] for a review).
DNMT1, DNMT3A, and DNMT3B enzymes are responsible for RASSF1Am in different
contexts [53–58]. RASSF1Am seems to follow a precise cascade of events with recruitment of
the complex HDAC1/SETDB1, that in turn attracts DNMT3A in cancer cells [58]. In lung cancer,
∆DNMT3B4 (DNMT3 that lacks exon 6) appears essential for RASSF1A silencing [55], while its high
methylation profile is driven by other epigenetic signals to support gene silencing architecture that
favors cancer growth [59].
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5mCs are recognized by methyl-binding proteins that in turn recruit histone modifying and
chromatin remodeling enzymes [60]. Capped 5mCs promote a closed chromatin structure by
obstructing the binding of transcription factors (inhibitors and enhancers of gene transcription) [61,62].
Somatic reprogramming is a dramatic demonstration of the impact of DNA methylation on cell fate [63].
5mCs are less frequent in the target sequences of transcription factors, or are selectively over-represented
in some CpG islands, but are yet influencing transcriptional programs [64], suggesting that fine-tuned
DNA methylation tends to be dynamically and functionally interconnected with cellular signaling
pathways [65] (see Du et al. [66] for a review).
4. Methylation of RASSF1A in Normal Tissues of the Gastroenteric System
RASSF1Am usually refers to the methylation of the CpG island A, which covers the promoter
and first exon of RASSF1A. There are few descriptions of the methylation status of RASSF1A at single
CpG resolution in normal gastrointestinal tissues. Heterogeneous distribution and level of 5mCs
in adjacent CpGs in the RASSF1A promoter and first exon was observed in the normal pancreas
adjacent to pancreatic endocrine tumors [67]. In these individuals, CpG methylation ranged from
absent to diffuse. Figure 2 shows the variable CpG methylation patterns found in five normal tissues
of a 34-year-old healthy individual. In this example, CpG methylation was higher in the liver and
pancreas and was almost absent in the esophagus, colon and, stomach. According to data reported in
Figure 2, unmethylated RASSF1A status was found in 15 stomach normal tissues [68]. The Cancer
Genome Atlas (TCGA) data confirmed a variable and higher RASSF1Am level in the normal liver and
pancreas compared to colon and stomach (see Section 7).
Figure 2. Methylation level of 48 CpGs in the promoter and first exon of RASSF1A in five normal
tissue types. Results of bisulfite DNA sequencing on liver, esophagus, pancreas, colon, and stomach
tissues samples taken from a 34-year-old healthy subject. The grey/blue vertical bars represent 48 CpGs
overlapped to the promoter of RASSF1A and partially to first exon and CpG island A. For each CpG,
the blue line is the number of reads for the 5mC and grey is the total number of reads (number of
reads per kilobase per million mapped reads, RPKM) obtained by bisulfite DNA sequencing. The ratio
between the two numbers represents the methylation level of a CpG. The grey bar at the bottom of the
figure identifies the 3′ end of the CpG island A. The data were retrieved by the WashUp EpiGenome
Browser at www.epigenomegateway.wustl.edu, provided by the Roadmap EpiGenome Project [69].
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5. Mechanisms of RASSF1A Methylation in Cancer and Aging
All cancers are characterized by some degree of global epigenetic alteration entailing general
DNA hypomethylation and abnormal hypermethylation in specific CpG islands. Alteration of DNA
methylation patterns may depend on altered methyl group transfer during DNA duplication, or
on defects of 5mC hydroxylation and demethylation operated by TET enzymes. In cancer and
during aging, a substantial fraction of genes undergo a cell type-specific DNA hypermethylation
of silenced genomic loci protein that is preceded by H3-K27 and H3-K9 trimethylations [70–76].
Analogously, an aberrant transcriptional silencing of RASSF1A triggered by the inactivating
chromatin modification histone deacetylation and H3-K9 methylation preceded CpG island A
hypermethylation [59] (see Klutstein et al. [77] for a review).
In differentiated cells, CpG islands particularly rich in CpGs and overlapped to gene
promoters, as those present in RASSF1A, remain mostly unmethylated, even when the gene is
inactive [59,78–80]. Thus, the occurrence of 5mCs in the CpG island A (Figure 2) could be considered as
a somatically acquired abnormal event that spreads through the core region to initiate gene silencing,
possibly reflecting distinct interactions among epigenetic machinery and components of the chromatin
responsible for transcriptional regulation. [75,81,82].
RASSF1A is hypermethylated in most cancer types, and in some cases also in the adjacent
normal tissues [1,83]. Aberrant RASSF1A promoter DNA methylation has been detected also
in childhood neoplasia, including neuroblastoma, thyroid carcinoma, hepatocellular carcinoma,
pancreatoblastoma, adrenocortical carcinoma, Wilms’ tumor, Burkitt’s lymphoma, and T-cell
lymphoma [78]. The methylation of CpGs in the promoter and first exon of RASSF1A shows
extreme variability in terms of distribution and relative levels of each CpG in single cell types, as well
as in cancer and normal tissues [10,27,67,68,84–90]. This may possibly reflect a cell type- and/or
clonal-based epigenetic heterogeneity.
It is reported that internal or environmental stimuli can promote epigenetic modifications
that spread as silent events [85]. For example, RASSF1Am increases during physiological or
patho-physiological processes such as aging, hypoxic conditions, senescence, inflammation, and viral
infection [30,75,77,91–95]. De novo RASSF1Am associates with different factors and conditions; folate
metabolism, DNA polymorphisms, as well as choline-deficient L-amino acid-defined diet in rats [96,97].
Early stages of estrogen-induced breast carcinogenesis in female rats is characterized by altered global
DNA methylation, aberrant expression of proteins responsible for maintenance of DNA methylation
pattern, and also by de novo RASSF1Am [98]. Transfection of hepatitis C virus core protein into hilar
cholangiocarcinoma cell lines inducesRASSF1A promoter DNA methylation and silencing [95]. In these
contexts, RASSF1Am would function as an epigenetic sensor, associated to physiologic and disease
conditions. The cell progeny could inherit a gene dosage pernicious for the RASSF1A-dependent cell
functions that remains altered for the entire life of the organism. According to this model, de novo
DNA methylation or demethylation at regulatory sites can anticipate the pathological transformation
in different cell phenotypes before transformation ensues (epigenetic field defect) [85,99,100].
An age-dependent increase of RASSF1Am at differing speeds in different organs of healthy
individuals is largely recapitulated in corresponding cancer types [74–77]. Thus, site-specific DNA
hypermethylations that overlap in aging and tumorigenesis candidate these sites as cancer susceptibility
hotspots. The epigenetic changes and the parallel increased risk of tumor onset occurring during aging
keep open the possibility of a causative role of epigenetic reprogramming in RASSF1A silencing in
support of progressive tumorigenesis.
6. Relationship between RASSF1A Methylation and Expression
The mechanisms that regulate DNA methylation and its consequences on gene transcription are
only partially understood. The relative levels and patterns of methylation at specific CpG sites along
the entire genome associate variably with gene expression [101]. More precisely, for each gene the
correlation can be both positive or negative in different cell types suggesting tissue-specificity [102].
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However, data relative to RASSF1 derived from omics techniques should be considered with caution
since the applied experimental procedures might have not been sufficiently sensitive and able to provide
high resolution data in the RASSF1 genomic region. RASSF1A expression is lost in different cancer
types, as in lung, breast, and kidney cancer [103,104]. Consistently, epigenetic loss of RASSF1A has been
proposed to serve as a diagnostic marker of clinical outcome in some cancer types [90,100,105–107].
There is currently poor understanding of the functional relevance of methylation of single CpG.
From a mechanistic point of view, the methylation of cytosines in the normally unmethylated CpG
island A can determine inhibitory cumulative effects on RASSF1A transcription due to the action
of methyl-binding proteins. In experiments based on reporter constructs containing an artificial
RASSF1A promoter with four groups of four CpGs at increasing distance from the transcription start
site, two separated clusters of four consecutive methylated CpGs (not other combinations) determined
a 63% decrease in promoter activity. Oct1 and Sp1 transcription factors bound preferentially to
regulatory sequences overlapped to the regulatory CpGs when unmethylated [108]. Volodko et al.
screened CpGs methylation and searched for correlation with RASSF1A transcription in various cancer
types [109]. In colorectal cancer, seven CpGs hotspot in the RASSF1A promoter have been described to
contribute to most of the DNA methylation. In breast and thyroid cancers, the methylation level of
single CpGs mirrors the average value for the whole promoter. In normal breast tissue, RASSF1A exon
1 is found methylated without affecting gene expression [87], whereas matched breast cancers tissues
show RASSF1A hypermethylation in both exon 1 and spreading towards the promoter region in
association with the gene silencing.
In pancreatic endocrine tumors (PET), it has been demonstrated that a down-modulation of
RASSF1A correlates with increased methylation of 51 CpG in the CpG island A and RASSF1C
expression [67]. An expression switch between RASSF1A and RASSF1C concomitant to CpG island A
hypermethylation has also been observed in breast cancer, neuroblastoma, some lung cancers [24,31],
esophageal squamous cell carcinoma [110], renal cell carcinoma [111], breast, thyroid, and colorectal
cancers [109], but not in pancreatic ductal adenocarcinoma [84]. RASSF1A is a Hippo pathway
scaffold protein that subtracts YAP1 from oncogenic TEAD (TEA domain) transcriptional complexes
and promotes tumor-suppressive YAP1/p73 activity [112]. RASSF1Am and alternated RASSF1A
and RASSF1C expression correlates with loss of inhibitor signals mediated by YAP1, E-cadherin
internalization and epithelial integrity is associated with an acquired invasive phenotype [113].
The alternated expression of distinct RASSF1 isoforms with opposing functions would explain
the association between loss of RASSF1A expression and an adverse outcome and disease progression
for certain cancer types, calling upon the need of more functional studies to better understand the
functional consequence of this switch. Furthermore, these data suggest that cell type-specific factors to
be discovered modulate the transcriptional silencing ofRASSF1A supported by the cytosine methylation.
7. RASSF1A Methylation and Expression in Gastrointestinal Cancers
By considering the published RASSF1Am data in gastrointestinal cancer types, the overall
frequency of RASSF1Am is 78% in hepatocellular carcinoma, 34.6% in hepatoblastoma, 50% in
esophageal squamous cell carcinoma, 54% in pancreatic ductal adenocarcinoma, 75% in PET, 35.6% in
CRC and 31% in gastric cancer (Table 1).
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Table 1. Frequency of RASSF1A methylation in gastrointestinal cancers *.
Cancer Type Methylation of RASSF1A
Hepatocellular carcinoma (HCC) 522 of 669 (78%) HCC
Hepatoblastoma (HB) 46 of 133 (34.6%) HB
Esophageal squamous cell carcinoma (ESCC) 442 of 884 (50%) ESCC
Pancreatic ductal adenocarcinoma (PDAC) 32 of 59 (54%) PDAC
Pancreatic endocrine tumor (PET) 114 of 175 (75%) PET
Colorectal carcinoma (CRC) 558 of 1567 (35.6%) CRC
Gastric cancer (GC) 179 of 378 (31%) GC
* see Tables S1 to S5 for experimental details and references.
Data from TCGA show that RASSF1Am is detected at higher frequency as compared to normal
tissues in liver, colorectal, and stomach cancers but not in pancreatic cancers (Figure 3).
The RASSF1Am data extracted from the literature and TCGA are consistent for liver, but not for
pancreatic, colorectal, and gastric cancers. For pancreatic cancer, 20% to 35% RASSF1Am shown by
TCGA data is close to the 35% reported by Amato et al. [84]. In general, differences of RASSF1Am may
depend from the assay types applied and assay location, as discussed earlier in this review. A detailed
description of the results and methods applied for the detection RASSF1Am in five gastrointestinal
cancer types and the corresponding normal tissues is reported in Tables S1 to S5. All TCGA data were
obtained by Illumina platforms. However, most of RASSF1Am data described in published studies
were obtained by methylation-specific PCR (MSP), a qualitative technique informative of one or few
CpGs. MSP tends to overestimate the frequency of DNA methylation as even few methylated CpGs
belonging to a small fractions of the genomes present in the sample will produce a positive signal [115].
Given these premises, a certain variability in the association between DNA methylation and expression
of RASSF1A or between RASSF1Am and the patients’ clinico-pathological parameters is expected to
be found.
RASSF1A hypermethylation is a common finding in all gastrointestinal cancer types often
along with other tumor suppressor genes in a pattern that is typical of CpG island methylator
phenotype (CIMP). CIMP is an epigenetic disorder, characterized by widespread and simultaneous
hypermethylation of CpG islands, that differentiates distinct subsets of cancer patients [116].
Genome-scale analysis found CIMP state generally concordant between primary colorectal cancers
(CRCs) and corresponding metastases [117]. RASSF1A is candidate gene of CIMP in colorectal
cancers [118] (see Weisenberger et al. [119] for e review).
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the promoter and 5′-UTR of RASSF1A (NM_007182) in colorectal, liver, pancreatic, and stomach 
cancers cases. T, tumor tissues (red), N, normal tissue (green). 5′-UTR is the 5′ untranslated region of 
the first exon of RASSF1A. The promoter region is defined as from 1.5 kb upstream to 0.5 kb 
downstream of the RASSF1A transcription start site. The graphs show the distribution of beta values 
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Figure 3. DNA methylation of the promoter and 5 -UTR of RASSF1A in colorectal, liver, pancreatic,
and stomach cancers and in the corresponding normal tissues. Distribution of average methylation in
the promoter and 5′-UTR of RASSF1A (NM_007182) in colorectal, liver, pancreatic, and stomach cancers
cases. T, tumor tissues (red), N, normal tissue (green). 5′-UTR is the 5′ untranslated region of the first
exon of RASSF1A. The promoter region is defined as from 1.5 kb upstream to 0.5 kb downstream of
the RASSF1A transcription start site. The graphs show the distribution of beta values calculated as
methylated probe intensity divided the unmethylated probe intensity plus methylated probe intensity,
lus 100. In the boxes, a horizontal line represents the median and the fille circle the average; the box
represents the 25th erce tile interval and the whiskers the 95th percentile interval of the distribution.
Empty points represent outliers. The doubl asterisk indicat s a significant difference b tween T and N
samples (p < 0.005) calculated by the t-test. The graphs, retrieved from the MethHC site [114], are based
on The Cancer Genome Atlas (TCGA) data.
RASSF1 isoforms expression is variable in different gastrointestinal cancer types (Figure 4).
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Figure 4. mRNA level of RASSF1A, RASSF1B, RASSF1C in seven gastrointestinal cancer types and the
corresponding normal tissues. Red box, cancer types; white box normal tissues. The box plots show
the expression distribution of the RASSF1 isoforms RASSF1A, RASSF1B, and RASSF1C in the cancer
types indicated in figure and the respective normal tissues. The expression levels of the samples are
represented by black points. The expression data are log2 of Transcripts Per Million plus 1 (TPM+1)
transformed for differential analysis and the log2 fold change defined as median of cancers minus
median of normal tissues. Expression data of cancer and normal samples derived from the TCGA.
Box plot represents the 25th percentile interval and whiskers represent the 95th percentile interval
of the distribution. A horizontal line indicates the median value of the expressions. The number
of samples for each series in cancers (T) and normal (N) is indicated below the acronym of cancer.
CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; LIHC,
liver hepatocellular carcinoma; PAAD, pancreatic adenocarcinoma; READ, rectum adenocarcinoma;
STAD, stomach adenocarcinoma. The asterisk indicates a significant difference of expression between
a cancer type and the corresponding normal tissues (p < 0.01). Graphs were obtained from GEPIA2 at
http://gepia2.cancer-pku.cn.
RASSF1A expression level is higher in stomach cancers and lower in liver cancers. RASSF1C level
is, in general, higher than RASSF1A and RASSF1B level. RASSF1C expression is significantly higher
in cancers than in normal tissues in cholangiocarcinoma and hepatocellular carcinoma (Figure 4).
Certain studies have reported a robust correlation between 5mCs distribution and RASSF1A mRNA
levels on one side, and methylation hotspots and transcription on the other. Concomitant RASSF1Am
increase and gene expression loss has been reported in many studies regarding gastrointestinal cancers
(Tables S1 to S5). However, TCGA data show no significant inverse correlation between promoter or
5′-UTR average DNA methylation and number of reads in colorectal, liver, pancreatic, and stomach
cancers. High stringency is observed for methylation in the shore elements of the CpG island A in
colorectal and stomach cancers (Figure 5).
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Figure 5. Average methylation of 15 CpGs in the CpG island A shore in function of the mRNA level of
RASSF1A in colorectal, liver, pancreatic, and stomach cancers. Average methylation of cytosines in
the CpG island A shore in function of the mRNA level (NM_007182) in colorectal, liver, pancreatic,
and stomach cancers. RASSF1A mRNA expression represent the number of reads per kilobase per
million mapped reads. CpG island A shore methylation correspond to the average methylation of
15 CpGs (chr3 from 50,378,611 to chr3:50,377,755, GRCh37/hg19). Red points, tumor tissues; green
points, normal tissues. Blue line represents the trend line through the points. Parameters of the trend
line, equation of the straight line, standard error, and correlation coefficient, are shown above graphs.
A significant inverse correlation between CpG island A methylation and RASSF1A expression is found
in colorectal and stomach cancers. The p-value of the trend line is indicated. The graphs, retrieved from
the MethHC site [114], are based on The Cancer Genome Atlas (TCGA) data.
Flanking regions of CpG islands, referred to as CpG island shores, showed tissue-specific DNA
hypermethylation and association with gene silencing in cancer [61,120]. Based on TCGA data,
CpG island A shore methylation correlated inversely with RASSF1A mRNA levels in colon and
stomach cancers, but not in liver and pancreatic cancers (Figure 5). An average methylation of the
whole RASSF1A promoter region higher than 20% results in a reduced RASSF1A mRNA expression in
various cancer cell lines, suggesting that it represents a critical threshold for efficient gene silencing [109].
At this degree of methylation, it is probable that in each genome some of the regulatory CpGs of a gene
are methylated, thereby establishing an efficient contrast to the transcription initiation complex.
8. Conclusions and Perspectives
Multiple lines of evidence demonstrate that loss of RASSF1A promotes cell transformation and
that epigenetic regulation by DNA methylation may be one of the responsible mechanisms in a wide
variety of malignancies. RASSF1Am is a widespread event in gastrointestinal cancers and promises
to serve as a valuable diagnostic/prognostic marker, making it possible to translate epigenomics into
clinical relevant information [121].
A large body of experimental data underline the importance of a controlled and adequate supply
of RASSF1A for correct functionality of cells, whereas it is questionable if the current knowledge
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about the DNA methylation pattern is sufficient to allow the exploitation of DNA methylation data
as a biomarker. Single CpGs may carry out specialized functions, in particular if they rule over the
binding of transcription factors acting as master tissue homeostasis regulators [62]. Our ability to
resolve unique patterns of methylation in complex arrays of different tissues is still limited and the
use of different, non-comparable, techniques for the detection of methylation and relative expression
of RASSF1A has counteracted its power as a reliable tumor marker and this limitation therefore
encourages to adopt more standardized methods.
Although DNA methylation data have long been considered a promising source of biomarkers
for cancer diagnosis, prognosis, and prediction, there are a few successful examples that confirmed
the previous findings and were applied to clinics [122]. Concerning RASSF1A, its methylation was
used a marker in a panel for the early detection of the hepatocellular carcinoma [90]. RASSF1Am was
applied to clinics as tissue biomarker only for prostate cancer [123].
It is believed that a biomarker based on DNA methylation does not necessarily have to be correlated
with gene expression. However, a correlation DNA methylation-gene expression provides a biological
rationale to support the clinical application as biomarker of the DNA methylation. Koch et al. have
used TCGA data on prostate cancer to assess the correlation between DNA methylation and mRNA
expression of RASSF1A [122]. They showed that different assays aimed at determining RASSF1Am
result in contradictory outcomes and insufficiently effective discriminating power (positive or negative
or no correlation between RASSF1A methylation and mRNA expression). Analogous conclusions
have been obtained for the methylation of other genes, suggesting that finding a reliable assay
location is needed [122]. The conclusions drawn by Koch et al. challenge the results of previous
studies on RASSF1Am and solicit a revision of available methods and strategies so far applied [122].
Well-designed/informative high resolution and quantitative DNA methylation and mRNA/protein
analyses are required.
The exact location of biologically and clinically relevant hypermethylation of RASSF1A,
with reference to specific contexts and pathologies, is still unknown. In addition to the promoter region,
attention should be paid at distal enhancers. An association between deregulated gene expression and
CpGs methylation in cancer may result significantly stronger for distal enhancers than the promoters
of many genes [124]. To our knowledge, the role of the methylation of distal enhancer sequences in the
RASSF1A expression regulation has never been established.
In conclusion, we do not know precisely why methylation of cytosines rises at a spot, if it originates
from a random process, and/or if it is acquired through selection. In addition, the inhibitory efficiency
of 5mCs at a certain CpG site on gene transcription is not easily predictable. The relevance of 5mCs at
specific CpG positions might regard the loss of binding of transcription factors and of communication
between signaling pathways and the functions powered by RASSF1A. Future DNA methylation
analyses should extend assay locations, provide the patterns of methylation in single or few genomes
complemented by the effect on the binding of transcription factors, and the consequent transcriptional
output [125]. The exploitation of this knowledge is of strategic importance for the correct interpretation
of the consequences that methylation plays on cellular function and to achieve robust associations
with clinical data.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/7/959/s1,
Table S1: RASSF1A methylation in liver neoplasms, Table S2: RASSF1A methylation in esophageal squamous cell
carcinoma, Table S3: RASSF1A methylation in pancreatic neoplasms, Table S4: RASSF1A methylation in colorectal
cancer, Table S5: RASSF1A methylation in gastric cancers.
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